This study was designed to evaluate the prognostic significance of BMM detection in patients with operable esophageal squamous cell carcinoma (ESCC) after long-term follow-up.
Nine patients with newly diagnosed, operable, non-small cell lung cancer (NSCLC) were imaged with FDG positron emission tomography/CT (PET), FLT PET/CT, and CT at baseline, following one cycle of neoadjuvant therapy (75 mg/m2 docetaxel + 75 mg/m2 cisplatin), and again after the second cycle of therapy.
In the 1990s, much interest was generated from two small trials that reported striking results with neo-adjuvant chemotherapy, and therefore our intergroup randomised trial was designed to investigate whether, in patients with operable non-small cell lung cancer of any stage, outcomes could be improved by giving platinum-based chemotherapy before surgery.
Indeed, while the majority of the investigators confirm that this marker augments tumor invasiveness and metastasis resulting in shorter DSS, in a recent study by Al-Saad et al., NF-kB p 105 was reported to have a favourable impact on DSS in operable non-small cell lung carcinoma patients [40].
In 2006, the International Adjuvant Lung Trial (IALT) bio-investigator group retrospectively reported that low vs high tumoural ERCC1 protein expression significantly predicted benefit from adjuvant cisplatin doublet chemotherapy in operable non-small cell lung cancer (NSCLC) (Olaussen et al, 2006).
PD-ECGF/TP expression was evaluated immunohistochemically in surgically resected specimens from 107 patients with operable non-small-cell lung cancer using the P-GF,44C monoclonal antibody.
Anatomic pulmonary lobectomy with radical lymph node dissection is the primary treatment for operable non-small-cell lung cancer (NSCLC) [ 1].
Excision of the primary tumour and the metastasis can be undertaken in patients with operable non-small-cell lung cancers and a single brain metastasis (standard, level of evidence: C) or adrenal gland metastasis (standard, level of evidence: D).
Among 36 patients with primary operable non-small-cell lung cancer (NSCLC), we detected seven (19.4%) with K-ras exon I mutations on tumour samples (Ferretti et al, 2000).
The current standard for treating operable early stage non-small cell lung cancer is surgical resection and for inoperable cases it is external beam radiotherapy.
